News Snapshot:
CanSinoBIO's COVID-19 mRNA vaccine receives approval for clinical trial application in China Global Times By Hu Yuwei Published: Apr 04, 2022 10:58 AM Chinese vaccine developer CanSinoBIO's COVID-19 mRNA vaccine has received approval for clinical trial application in China, the company announced on Monday, an encouraging step for domestic mRNA vaccine R&D amid the recent infection wave across China. Pre-clinical trial results showed that CanSinoBIO's COVID-19 mRNA vaccine can induce high-titer neutralizing antibody levels against multiple SARS-CoV-2 variants of concern (VOC) identified by the World Health Organization (WHO), including the Omicron variant, a highly transmissible and dominant strain circulating in...
